BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND SRC, c-SRC, 6714, ENSG00000197122, P12931, ASV, p60-Src, SRC1, c-src AND Treatment
98 results:

  • 1. Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian Oncology Centre.
    Gutic B; Bozanovic T; Mandic A; Dugalic S; Todorovic J; Dugalic MG; Sengul D; Detanac DA; Sengul I; Detanac D; Kesicioglu T; Soares Junior JM
    Clinics (Sao Paulo); 2023; 78():100204. PubMed ID: 37148829
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
    Chien W; Tyner JW; Gery S; Zheng Y; Li LY; Gopinatha Pillai MS; Nam C; Bhowmick NA; Lin DC; Koeffler HP
    J Ovarian Res; 2023 Apr; 16(1):80. PubMed ID: 37087441
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
    Jiang Y; Song L; Lin Y; Nowialis P; Gao Q; Li T; Li B; Mao X; Song Q; Xing C; Zheng G; Huang S; Jin L
    Oncogene; 2023 May; 42(20):1672-1684. PubMed ID: 37020040
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. src-3/TRAF4 facilitates ovarian cancer development by activating the PI3K/AKT signaling pathway.
    Wang Y; Luo X; Wu N; Liao Q; Wang J
    Med Oncol; 2023 Jan; 40(2):76. PubMed ID: 36625999
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Developing and Testing Methylated Nano-Structured Dipeptides that Inhibit src Kinase Activity In Vitro for Anti-cancer Applications.
    Nahhas AF; Nahhas AF; Webster TJ
    J Vis Exp; 2022 Nov; (189):. PubMed ID: 36533825
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Novel Approaches for the Solid-Phase Synthesis of Dihydroquinazoline-2(1
    Wang Q; Pan Y; Luo H; Zhang Y; Gao F; Wang J; Zheng J
    Molecules; 2022 Dec; 27(23):. PubMed ID: 36500678
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
    Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
    Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
    [No Abstract]    [Full Text] [Related]  

  • 8. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
    Marinelli LM; Kisiel JB; Slettedahl SW; Mahoney DW; Lemens MA; Shridhar V; Taylor WR; Staub JK; Cao X; Foote PH; Burger KN; Berger CK; O'Connell MC; Doering KA; Giakoumopoulos M; Berg H; Volkmann C; Solsrud A; Allawi HT; Kaiser M; Vaccaro AM; Albright Crawford C; Moehlenkamp C; Shea G; Deist MS; Schoolmeester JK; Kerr SE; Sherman ME; Bakkum-Gamez JN
    Gynecol Oncol; 2022 Jun; 165(3):568-576. PubMed ID: 35370009
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis.
    Zhang J; Li Y; Liu H; Zhang J; Wang J; Xia J; Zhang Y; Yu X; Ma J; Huang M; Wang J; Wang L; Li Q; Cui R; Yang W; Xu Y; Feng W
    J Exp Clin Cancer Res; 2022 Jan; 41(1):24. PubMed ID: 35033172
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy Experience in Peritoneal Carcinomatosis: Single-Center Analysis of 180 Cases.
    Karadayi K; Bostanci ME; Mollaoglu MC; Karabacak U
    Int J Surg Oncol; 2021; 2021():8851751. PubMed ID: 33976936
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Dysregulated Immunological Functionome and Dysfunctional Metabolic Pathway Recognized for the Pathogenesis of Borderline ovarian Tumors by Integrative Polygenic Analytics.
    Chang CM; Li YF; Lin HC; Lu KH; Lin TW; Liu LC; Su KM; Chang CC
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921111
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer.
    Erdogan MA; Ashour A; Yuca E; Gorgulu K; Ozpolat B
    Cell Signal; 2021 May; 81():109938. PubMed ID: 33539938
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. BET, src, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
    Lui GYL; Shaw R; Schaub FX; Stork IN; Gurley KE; Bridgwater C; Diaz RL; Rosati R; Swan HA; Ince TA; Harding TC; Gadi VK; Goff BA; Kemp CJ; Swisher EM; Grandori C
    EBioMedicine; 2020 Oct; 60():102988. PubMed ID: 32927276
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. IGF2BP1 is a targetable src/MAPK-dependent driver of invasive growth in ovarian cancer.
    Bley N; Schott A; Müller S; Misiak D; Lederer M; Fuchs T; Aßmann C; Glaß M; Ihling C; Sinz A; Pazaitis N; Wickenhauser C; Vetter M; Ungurs O; Strauss HG; Thomssen C; Hüttelmaier S
    RNA Biol; 2021 Mar; 18(3):391-403. PubMed ID: 32876513
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Progesterone decreases ovarian cancer cells migration and invasion.
    Lima MA; Silva SV; Jaeger RG; Freitas VM
    Steroids; 2020 Sep; 161():108680. PubMed ID: 32562708
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer.
    Gong G; Lin T; Yuan Y
    J Ovarian Res; 2020 Mar; 13(1):30. PubMed ID: 32192517
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Cyclin-dependent kinase 1-mediated phosphorylation of YES links mitotic arrest and apoptosis during antitubulin chemotherapy.
    Wang Z; Chen X; Zhong MZ; Yang S; Zhou J; Klinkebiel DL; Karpf AR; Chen Y; Dong J
    Cell Signal; 2018 Dec; 52():137-146. PubMed ID: 30223016
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Dual src and MEK Inhibition Decreases ovarian cancer Growth and Targets Tumor Initiating Stem-Like Cells.
    Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
    Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
    [No Abstract]    [Full Text] [Related]  

  • 19. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
    Rada M; Nallanthighal S; Cha J; Ryan K; Sage J; Eldred C; Ullo M; Orsulic S; Cheon DJ
    Oncogene; 2018 Aug; 37(35):4809-4820. PubMed ID: 29769618
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Trans10,cis12 conjugated linoleic acid inhibits proliferation and migration of ovarian cancer cells by inducing ER stress, autophagy, and modulation of src.
    Shahzad MMK; Felder M; Ludwig K; Van Galder HR; Anderson ML; Kim J; Cook ME; Kapur AK; Patankar MS
    PLoS One; 2018; 13(1):e0189524. PubMed ID: 29324748
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.